CD274 and neoplasm: In this study, we investigated if the treatment of TGF-β receptor 1 selective small molecule kinase inhibitor, termed LY364947 [33], can enhance the antitumor efficacy of anti-PD-L1 mAb in immunogenic (MC38 colorectal tumor) and poorly immunogenic (KPC1 pancreatic tumor) tumor models.